Also Included In: Psychology / Psychiatry; Neurology / Neuroscience
Article Date: 01 Nov 2011 - 1:00 PDT
email to a friend 
printer friendly 
opinions 
A new report in Biological Psychiatry suggests that deficits in endocannabinoid function may contribute to anorexia nervosa and bulimia. Endocannabinoids are substances made by the brain that affect brain function and chemistry in ways that resemble the effects of cannabis derivatives, including marijuana and hashish. These commonly abused drugs are well known to increase appetite, i.e. to cause the "munchies". Thus, it makes sense that deficits in this brain system would be associated with reduced appetite.
Researchers measured the status of the endocannabinoid system indirectly by determining whether there was an increase or decrease in the density of endocannabinoid receptors, called the CB1 receptor, in several brain regions using positron emission tomography, or PET, imaging. They compared these densities in women with anorexia or bulimia with those of healthy women.
They found global increases in ligand binding to CB1 receptors in the brains of women with anorexia nervosa. This finding is consistent with a compensatory process engaged by deficits in endocannabinoid levels or reduced CB1 receptor function.
CB1R availability was also increased in the insula in both anorexia and bulimia patients. The insula "is a region that integrates body perception, gustatory information, reward and emotion, functions known to be disturbed in these patients," explained Dr. Koen Van Laere, the study's lead author.
"The role of endocannabinoids in appetite control is clearly important. These new data point to important connections between this system and eating disorders," added Dr. John Krystal, Editor of Biological Psychiatry.
Additional research is now needed to establish whether the observed changes are caused by the disease or whether these are neurochemical alterations that serve as risk factors for developing an eating disorder.
Furthermore, since very few effective treatments exist for these disorders, these data indicate that the endocannabinoid system may be a potential new target for developing drugs to treat eating disorders. Such new therapies are currently being investigated in animal models.
Article adapted by Medical News Today from original press release. Source: ElsevierVisit our eating disorders section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:
MLA
8 Dec. 2011.
Please note: If no author information is provided, the source is cited instead.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
